Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review

References

• Sikora K. Genetic approaches to cancer therapy. Gene Ther. 1994; 1: 149–151
   PubMed Web of Science ®Google Scholar
• Loeffler J.S., Alexander E., Shea W.M., et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol. 1992; 10: 1379–1385
   PubMed Web of Science ®Google Scholar
• Mahaley M.S., Mettlin C., Natarajan N., et al. National survey of patterns of care for brain tumor patients. J. Neurosurg. 1989; 71: 826–836
   PubMed Web of Science ®Google Scholar
• Southam C.M. Present status of oncolytic virus studies. N. Y. Acad. Sci. 1960; 22: 656–673
   Google Scholar
• Martuza R.L., Malick A., Markert J.M., et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854–856
   PubMed Web of Science ®Google Scholar
• Rochlitz C.F. Gene therapy of cancer. Swiss Med. Wkly 2001; 131: 4–9
   PubMed Web of Science ®Google Scholar
• Wasil T., Buchbnder A. Gene therapy in human cancer: report of human clinical trials. Cancer Investig. 2000; 18: 740–746
   PubMed Web of Science ®Google Scholar
• Roizman B., Sears A.E. Herpes simplex viruses and their replication, B.N. Fields, D.M. Knipe, P.M. Howley. 3rd Ed., Lippincott-Raven Publishers, Philadelphia 1996; 2231–2295
   Google Scholar
• Corey L., Spear P.G. Infections with herpes simplex viruses. N. Engl. J. Med. 1986; 314: 686–691
   PubMed Web of Science ®Google Scholar
• Sears A.E., Halliburton I.W., Meignier B., et al. Herpes simplex virus 1 mutant deleted in the α22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J. Virol. 1985; 55: 338–346
   PubMed Web of Science ®Google Scholar
• Markovitz N.S., Roizman B. Replication-competent herpes simplex viral vectors for cancer therapy. Adv. Virus Res. 2000; 55: 409–425
   PubMed Web of Science ®Google Scholar
• Markert J.M., Malick A., Coen D.M., et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simples mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597–603
   PubMed Web of Science ®Google Scholar
• Boviatsis E.J., Park J.S., Sena-Esteves M., et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994; 54: 5745–5751
   PubMed Web of Science ®Google Scholar
• Pyles R.B., Thompson R.L. Evidence that herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. Virol. 1994; 68: 4963–4972
   PubMed Web of Science ®Google Scholar
• Chambers R., Gillespie G.Y., Soroceanu L., et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl Acad. Sci. USA 1995; 92(5)1411–1415
   PubMed Web of Science ®Google Scholar
• MacLean A.R., Ul-Fareed M., Robertson L., et al. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence. J. Gen. Virol. 1991; 72: 631–639
   PubMed Web of Science ®Google Scholar
• Mineta T., Rabkin S.D., Yazaki T., et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995; 1: 938–943
   PubMed Web of Science ®Google Scholar
• Kramm C.M., Chase M., Herrlinger U., et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 1997; 8: 2057–2068
   PubMed Web of Science ®Google Scholar
• Chung R.Y., Saeki Y., Chiocca E.A. B-myb promoter retargeting of herpes simplex virus γ34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 1999; 73: 7556–7564
   PubMed Web of Science ®Google Scholar
• Pyles R.B., Warnick R.E., Chalk C.L., et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 1997; 8: 533–544
   PubMed Web of Science ®Google Scholar
• Todo T., Martuza R.L., Rabkin S.D., et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. PNAS 2001; 98: 6396–6401
   PubMed Web of Science ®Google Scholar
• Meignier B., Longnecker R., Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 1988; 158: 602–614
   PubMed Web of Science ®Google Scholar
• Thompson R.L., Stevens J.G. Biological characterization of a herpes simplex virus intertypic recombinant which is completely and specifically non-neurovirulent. Virology 1983; 131: 171–179
   PubMed Web of Science ®Google Scholar
• Goldstein, D.J.; Weller, S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196–205.
   Google Scholar
• Brown S.M., MacLean A.R., McKie E.A., et al. The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with the proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34. J. Virol. 1997; 71: 9442–9449
   PubMed Web of Science ®Google Scholar
• Andreansky S.S., He B., Gillespie G.Y., et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl Acad. Sci. USA 1996; 93: 11313–11318
   PubMed Web of Science ®Google Scholar
• Rampling R., Cruickshank G., Papanastassiou V., et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000; 7: 859–866
   PubMed Web of Science ®Google Scholar
• Wang Q., Guo J., Jia W. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther. 1997; 4: 1300–1304
   PubMed Web of Science ®Google Scholar
• Mohr I., Gluzman Y. A herpes virus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996; 15: 4759–4766
   PubMed Web of Science ®Google Scholar
• Markert J.M., Medlock M.D., Rabkin S.D., et al. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7: 867–874
   PubMed Web of Science ®Google Scholar
• Meigner B., Longnecker R., Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J. Infect. Dis. 1988; 158: 602–614
   PubMed Web of Science ®Google Scholar
• Aghi M., Chou T.C., Suling K., et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 1999; 59: 3861–3865
   PubMed Web of Science ®Google Scholar
• Caroll N.M., Chase M., Chiocca E.A., et al. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res. 1997; 69: 413–417
   PubMed Web of Science ®Google Scholar
• Andreansky S., Soroceanu L., Flotte E.R., et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997; 57: 1502–1509
   PubMed Web of Science ®Google Scholar
• Schellingerhout D., Rainov N.G., Breakefield X.O., et al. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther. 2000; 7: 1648–1655
   PubMed Web of Science ®Google Scholar
• Bennett J.J., Tjuvajev J., Johnson P., et al. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat. Med. 2001; 7: 859–863
   PubMed Web of Science ®Google Scholar
• Kramm C.M., Sena-Esteves M., Barnett F.H., et al. Gene therapy for brain tumors. Brain Pathol. 1995; 5: 345–381
   PubMed Web of Science ®Google Scholar
• Kramm C.M., Rainov N.G., Sena-Esteves M., et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum. Gene Ther. 1996; 7: 1989–1994
   PubMed Web of Science ®Google Scholar
• Barnett F.H., Rainov N.G., Ikeda K., et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. 1999; 6: 14–20
   PubMed Web of Science ®Google Scholar
• Herrlinger U., Kramm C.M., Aboody-Gutterman K.S., et al. Pre-existing herpes simplex virus-1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by an HSV-1 vector. Gene Ther. 1998; 5: 809–819
   PubMed Web of Science ®Google Scholar
• Ikeda K., Ichikawa T., Wakimoto H., et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 1999; 5: 881–889
   PubMed Web of Science ®Google Scholar
• Ikeda K., Wakimoto H., Ichikawa T., et al. Complement depletion facilitates the infection of multiple brain tumors by intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 2000; 74: 4765–4775
   PubMed Web of Science ®Google Scholar
• Chahlavi A., Rabkin S.D., Todo T., et al. Effects of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999; 6: 1751–1758
   PubMed Web of Science ®Google Scholar
• Delman K.A., Bennett J.J., Zager J.S., et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. 2000; 11: 2465–2472
   PubMed Web of Science ®Google Scholar
• Chase M., Chung R.Y., Chiocca E.A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 1998; 16: 444–448
   PubMed Web of Science ®Google Scholar
• Guffey, M.B.; Luckett, W.S.; Gillespie, G.Y.; et al. Genetically engineered HSV-1 expressing bacterial cytosine deaminase for experimental murine brain tumor therapy. 24th International Herpesvirus Workshop 13.020, 1999.
   Google Scholar
• Moriuchi S., Oligino T., Krisky D., et al. Enhanced tumor-cell killing in the presence of ganciclovir by HSV-1 vector-directed co-expression of human TNF-α and HSV thymidine kinase. Cancer Res. 1998; 58: 5731–5737
   PubMed Web of Science ®Google Scholar
• Chahlavi A., Todo T., Martuza R.L., et al. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162–169
   PubMedGoogle Scholar
• Toyoizumi T., Mick R., Abbas A.E., et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 1999; 10: 3013–3029
   PubMed Web of Science ®Google Scholar
• Advani S.J., Sibley G.S., Song P.Y., et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998; 5: 160–165
   PubMed Web of Science ®Google Scholar
• Spear M.A., Sun F., Eling D.J., et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther. 2000; 7: 1051–1059
   PubMed Web of Science ®Google Scholar
• Kuo M.L., Kinsella T.J. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res. 1998; 58: 2245–2252
   PubMed Web of Science ®Google Scholar
• Niranjan A., Moriuchi S., Lunsford L.D., et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNFa and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol. Ther. 2000; 2: 114–120
   PubMed Web of Science ®Google Scholar
• Meigner B., Martin B., Whitley R.J., et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 1990; 162: 313–321
   PubMed Web of Science ®Google Scholar
• Hunter W.D., Martuza R.L., Feigenbaum F., et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in primates. J. Virol. 1999; 73: 6319–6326
   PubMed Web of Science ®Google Scholar
• Wikstrand C.J., McLendon R.E., Friedman A.H., et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRVIII. Cancer Res. 1997; 57: 4130–4140
   PubMed Web of Science ®Google Scholar